Trials / Completed
CompletedNCT02045836
Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 865 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the immunogenicity, reactogenicity and safety of the GSK Biologicals HZ/su candidate vaccine when its first dose is co-administered with Pneumovax 23™ vaccine in adults aged 50 years or older.The impact of HZ/su vaccine on Pneumovax 23™ vaccine immune response will also be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Herpes Zoster vaccine GSK 1437173A | 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm. |
| BIOLOGICAL | Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™ | One dose administered intramuscularly (IM) in the deltoid region of the non-dominant arm. |
Timeline
- Start date
- 2014-03-05
- Primary completion
- 2015-07-02
- Completion
- 2016-06-17
- First posted
- 2014-01-27
- Last updated
- 2021-05-14
- Results posted
- 2017-07-05
Locations
9 sites across 3 countries: United States, Canada, Estonia
Source: ClinicalTrials.gov record NCT02045836. Inclusion in this directory is not an endorsement.